Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CymaBay Therapeutics (GB:0I5P)
LSE:0I5P
RESEARCH TOOLSreports
CymaBay Therapeutics (0I5P) Share Price & Analysis
0 Followers
0I5P Stock Chart & Stats
Day’s Range$32.48 - $32.48
52-Week Range― - ―
Previous Close$32.48
Volume0.00
Average Volume (3M)N/A
Market Cap
$3.73B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.50Price Target Upside0.05% Upside
Rating ConsensusHold
Number of Analyst Covering11
CymaBay Therapeutics News
PremiumCompany Announcements
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul
PremiumCompany Announcements
CymaBay Therapeutics Revamps Executive Compensation Agreements
0I5P FAQ
What was CymaBay Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is CymaBay Therapeutics’s market cap?
Currently, no data Available
When is CymaBay Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CymaBay Therapeutics’s earnings last quarter?
Currently, no data Available
Is CymaBay Therapeutics overvalued?
According to Wall Street analysts CymaBay Therapeutics’s price is currently Undervalued.
Does CymaBay Therapeutics pay dividends?
CymaBay Therapeutics does not currently pay dividends.
What is CymaBay Therapeutics’s EPS estimate?
CymaBay Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CymaBay Therapeutics have?
Currently, no data Available
What happened to CymaBay Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CymaBay Therapeutics?
Among the largest hedge funds holding CymaBay Therapeutics’s share is RA Capital Management. It holds CymaBay Therapeutics’s shares valued at 164M.
---
CymaBay Therapeutics Stock Smart Score
Company Description
CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
---
0I5P Stock 12 Months Forecast
Average Price Target
$32.50
▲(0.05% Upside)
Technical Analysis
CymaBay Therapeutics
―
Achieve Life Sciences
―
Evoke Pharma
―
Galectin Therapeutics
―
Eloxx Pharmaceuticals
―
Best Analysts Covering 0I5P
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+141.10%
initiated a buy rating 8 months ago
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +141.10% per trade.
---